by barry-jtcir | Nov 14, 2024 | Press Releases
$13.9 million in gross proceeds raised since the beginning of 2024 extending expected cash runway into mid Q1 2025 and through interim data readout from GRI-0621 Phase 2a biomarker study Topline data of GRI-0621 readout expected in Q2 2025 Currently available...
by barry-jtcir | Oct 24, 2024 | Press Releases
Proceeds from recent exercise of warrants estimated to extend cash runway into mid Q1 2025, including interim data readout from Phase 2a biomarker study of lead program, GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (IPF) Current treatment options for...
by barry-jtcir | Oct 21, 2024 | Press Releases
LA JOLLA, CA, Oct. 21, 2024 — GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic and...
by barry-jtcir | Oct 16, 2024 | Press Releases
Data suggest that NKT cells are activated in airways in Idiopathic Pulmonary Fibrosis (IPF) patients and inhibition of iNKT cell activity can treat bleomycin-induced pulmonary fibrosis Company advancing Phase 2a biomarker study of GRI-0621 in patients with IPF with...
by barry-jtcir | Oct 7, 2024 | Press Releases
LA JOLLA, CA, Oct. 07, 2024 — GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic and...
